Categories: News

Inspire Medical Systems, Inc. to Report First Quarter 2024 Financial Results on May 7, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

MINNEAPOLIS, April 02, 2024 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the first quarter 2024 after the close of trading on Tuesday, May 7. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire’s Q1 2024 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Inspire’s Q1 2024 earnings call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call. 

Following the call, a replay will be available on the Company’s Investor Relations website approximately two hours after the event and archived on the site for two weeks.

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443

Staff

Recent Posts

Defence Therapeutics to Attend Bio International Convention in Boston, June 2025

Montreal, Quebec--(Newsfile Corp. - May 28, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF)…

34 minutes ago

AirStrip® Introduces Alarm Management: A Game-Changing FDA Approved Integrated Platform Transforming Clinical Alarm Management of Vital Signs

SAN ANTONIO, Texas--(BUSINESS WIRE)--AirStrip, a leader in vendor-agnostic clinical surveillance and decision support technologies, today…

11 hours ago

Rapid Dose Announces Proposed Equity Private Placement Financing

Burlington, Ontario--(Newsfile Corp. - May 27, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT"…

11 hours ago

AI-Powered Wearable Cuts Cancer Deaths by 90%— Redefines Infection Detection in Chemotherapy

Findings Released in ASCO Abstract Validate Life-Saving Impact of AION TempShield’s Long-Term Temperature Tracking for…

14 hours ago

Awakn Life Sciences Announces Completion of Arrangement and Sale to Solvonis Therapeutics plc

Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Awakn Life Sciences Corp. (CSE: AWKN) (OTC…

16 hours ago